Vumerity (diroximel fumarate) is a prescription drug that treats certain kinds of relapsing multiple sclerosis (MS). Vumerity comes as a delayed-release oral capsule that’s usually taken twice per day ...

Biogen’s Tecfidera follow-up Vumerity hit the market late last year, but eight months into the launch, the new multiple sclerosis drug is yet to meaningfully take off. The drug generated only $11 ...

“With MS, finding the right treatment option is as much about managing the clinical aspects of the disease as it is about how treatment fits into a person’s life,” said Simon Faissner, M.D., PhD, ...

Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales.

CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Results from the EVOLVE-MS-1 study show Vumerity was ...

Share on Pinterest Doctors expect people with MS will stick to their treatments with Vumerity because it has fewer side effects. Getty Images The FDA has approved Vumerity, a new drug to treat ...

Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis The MHRA has granted marketing authorisation for diroximel fumarate as oral treatment for ...

Biogen’s Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium (SMC) as an oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most ...

A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis The Committee for Medicinal Products for Human Use (CHMP) has recommended Vumerity ...

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of ...

– VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability – CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 ...